Tackling Challenges in Clinical Development


215 First Street
First Floor Seminar Room
Cambridge, MA 02142
United States

Tuesday, 30 April 2019 - 8:30am to 12:00pm

View Event Page


This half-day workshop is designed for professionals learning about the complexities of clinical trials and how to bring a new therapeutic to market. We have prepared an interactive, case-based learning experience to help participants better understand how to create a clinical development strategy, and how to manage in the face of unexpected challenges. Participants will actively make decisions about the trajectory of a specific clinical development project, and will have pieces of Mark's real life journey revealed step by step through the case discussion.

Breakfast will be provided at registration.

Who should attend:

  • Biomedical researchers
  • Clinicians
  • Early career clinical researchers
  • Biotech business development professionals

What you will learn:

  • Prioritizing and selecting clinical development projects
  • Creating and using target product profiles
  • Deciding on the right clinical trial strategy for your indication
  • Addressing unexpected challenges during the clinical development process

About the Instructor: Dr. Mark Goldberg, MD

Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. He served as a medical and regulatory strategist for Synageva BioPharma Corp., a biopharmaceutical company, from October 2014 until June, 2015. Prior to that, he served as the Executive Vice President for Medical and Regulatory Strategy of Synageva from January 2014 to October 2014 and as the Senior Vice President of Medical and Regulatory Affairs of Synageva from September 2011 to January 2014. Dr. Goldberg served as Senior Vice President and Therapeutic Group Head for Oncology, Genetic and Neurodegenerative Diseases Clinical Development at Genzyme. Dr. Goldberg currently serves on the board of directors of ImmunoGen, Inc., GlycoMimetics, Inc., Blueprint Medicines, Idera Pharaceuticals, and aTyr Pharma, all publicly traded companies. He is currently the chair-elect of the American Cancer Society’s New England Division Board.